眼内レンズの世界市場（2024年）：2023年～2029年の分析

当レポートでは、世界の単回使用眼科手術用製品市場について調査し、市場の概要とともに、今後5年間の市場パフォーマンス予測、重要な将来動向、および市場に参入する企業34社の企業プロファイルなどを提供しています。

サンプルビュー

目次

• 世界の白内障罹患率と白内障手術に関する情報
• 世界の白内障手術件数の現状と5年予測
• 両側同時白内障手術の採用予測
• 老眼、屈折異常、屈折矯正レンズ交換術に関する考察
• 5種類の老視矯正眼内レンズ（PC-IOL）の国・地域別売上高予測
• PC-IOLの標準バージョンとトーリックバージョンの売上予測
• モノビジョンとミニモノビジョンの国・地域別予測
• 米国の白内障および白内障/屈折矯正外科医のプロファイル
• 現在の償還水準についての考察
• 新しいプレミアムIOL技術の説明
• 新しい眼内レンズの改良についての考察
• 眼内レンズ注入器市場の調査

What's New:

The "2024 IOL Market Report" provides a new, extensive historical analysis of the market, recapping key events and market trends from the previous year and examining 2017-to-2023 sales by region for monofocal, presbyopia-correcting, toric, and other IOLs. This analysis also provides a view of 2023 sales for monofocal and premium IOLs by company tier.

The report reviews and analyzes the large number of EDOF and trifocal IOLs that were launched in Q4-2023. It also features survey data showing how the increasing popularity of monofocal plus IOLs is slowing the adoption of PC-IOLs.

In addition, the new report examines the challenges and opportunities created by the wave of the post-LVC cataract patients that is making IOL selection and surgery more challenging.

SAMPLE VIEW

The "2024 IOL Market Report" provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.

This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The "2024 IOL Market Report" offers a comprehensive look at the global IOL market, with eight regional/economic breakouts. The following information is included in this report:

• Information on cataract incidence and cataract surgeries worldwide.
• Current estimates and five-year forecasts for global cataract surgery volume.
• Forecasts for adoption of simultaneous bilateral cataract surgery.
• Discussion of presbyopia, refractive errors, and refractive lens exchange procedures.
• Forecasts for sales of five types of presbyopia-correcting IOLs (PC-IOLs) by country/region.
• Forecasts for sales of standard and toric versions of PC-IOLs.
• Forecasts for monovision and mini-monovision by country/region.
• Profiles of cataract and cataract/refractive surgeons in the US.
• Discussion of current reimbursement levels.
• Descriptions of new premium IOL technologies.
• Discussion of new IOL enhancements.
• Examination of the IOL injector market.
• Analysis of IOL companies' sales/marketing coverage in 31 major countries, showing whether each company has a direct presence, works with distributors, or has no coverage in each country.

Author Profile:

William Freeman

Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.

Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.